Agenda
Virtual, 19 - 21 May 2021
Schedule
Create your personal agenda –check the favourite icon
May 1910:50
Conference pass
Welcome, introduction, housekeeping
Keynotes
Jessica Robinson, Project director, Terrapinn Ltd
May 1911:00
Conference pass
Clinical Progress & Global Competition in BCMA-targeted Immunotherapy
Keynotes
- Multiple myeloma remain as an “incurable” cancer?
- Clinical progress of CAR-T therapy in multiple myeloma
- Competitive landscape of BCMA targeted therapy in early-stage commercial development
May 1911:30
Conference pass
Keynote panel discussion: State of the industry panel
Keynotes
- How have events over the last 12 months affected the industry? Maintaining
- Where is the ATMP field headed?
- Who is making the best progress?
- What is new on the market?
- The Next Wave: moving beyond CAR-T and Gene Therapy, what’s next?
Vivienne Parry, Head Of Engagement, Genomics England
Pascal Touchon, President, Chief Executive Officer And Board Member, Atara Biotherapeutics
Dick Sundh, Vice President, Marketing & Head of Australia, Canada and Europe (ACE),, Kite Pharma, a Gilead Company
May 1912:00
Conference pass
Keynote panel discussion: How to ensure clinical success
Keynotes
- Perfecting the art of regulatory submissions from pre-IND to final registration
- How can we avoid idiosyncratic clinical responses to ATMPs?
- Renewed guidance: are regulatory agencies changing how they view these approvals?
- Safety and clinical considerations:Robust, novel pre-clinical models and standardised assaysWhat in vitro tests and animal models can you use to minimise clinical risk?What can you really extrapolate from preclinical investigation to humans?How much should you expand cells? Is a high or low cell dose important?Pharmacogenetics, biodistribution, toxicology.
- Justification for routes of administration: what do the regulators think about delivery methods?
Debra Miller, CEO & Founder, CureDuchenne
Janet Glassford, Senior Quality Assessor, Medicines & Healthcare Products Regulatory Agency
May 1912:30
Conference pass
Roundtable with the regulators: Ensuring clinical success
Keynotes
- How do we move ahead?
- Why is it important?
- What’s the case to be made?
- Why is it important that we get there?
- Are there things we can do?
- Smaller vs larger patient populations
Debra Miller, CEO & Founder, CureDuchenne
Janet Glassford, Senior Quality Assessor, Medicines & Healthcare Products Regulatory Agency
May 1913:30
Conference pass
Panel discussion: Rise of allogeneic cells and allo-approaches to oncology & non-oncology
Cell Therapy
·The cell types·Impact of gene editing·Cellular Persistence·Cellular phenotypes·Expansion In vivo·Possibility of retreatment·Lymphodepletion·Administration of the cells/ Amount of the cells/Local and systemic administration
Stefanos Theoharis, Chief Business Officer, Bone Therapeutics
Pascal Touchon, President, Chief Executive Officer And Board Member, Atara Biotherapeutics
Patrick J Hanley, Chief and Director, Cellular Therapy Program, Children's National Medical Center
May 1913:30
Conference pass
CAR T-cell combination immunotherapy for solid tumors
Gene Modified Cell Therapy
·Discuss preclinical strategies for combination immunotherapy with CAR T cells·Highlight ongoing clinical trials of combination immunotherapy·Outline next-gen combination therapy strategies
May 1913:30
Conference pass
Panel: Tackling novel challenges: focusing on elements which are different from other cell culture processes
Manufacturing
- Low volume processing
- Uncertainty over raw and starting materials: How can we process properly if we don’t know the properties of the starting materials?
- How do we cope with variability in design?
Jan Schrooten, CEO & Co-Founder, Antleron
May 1913:30
Conference pass
Providing a novel off-the-shelf implant to repair damaged organs
Innovation
(1st Indication: Oesophagus)
Derek Dashti, Founder And Chief Executive Officer, D and P Bioinnovations
May 1914:00
Conference pass
Panel: The next generation of cell therapies
Cell Therapy
- Revisiting MSCs, what have we learned?
- Repurposed tools and modified cells
- Sourcing clinical grade iPSCs
Miguel Forte, Chief Executive Officer, Bone Therapeutics
Hardy Tadahisa S Kagimoto, President And Chief Executive Officer, Healios K. K.
Frank Barry, Scientific Director, Regenerative Medicine Institute
May 1914:00
Conference pass
Gamma delta T-Cells: Potential off the shelf treatment for solid tumours
Gene Modified Cell Therapy
·Circulating gamma delta T-cells expand more efficiently in the presence of TGF beta·These cells also exhibit superior fitness and resistance to cell death·TGFb supplemented gamma delta T-cells display enhanced anti-tumour activity, either when unmodified or genetically targeted using a CAR
May 1914:00
Conference pass
Panel: Automation of CGT manufacturing workflows for industrial scale
Manufacturing
Panelists will share their holistic view on integrated vs. automated manufacturing systems
Robin Ng, Strategy Lead, Cellular Biomedicine Group
Farid Ighemat, Senior Director Cell and Gene Therapy, GlaxoSmithKline
May 1914:00
Conference pass
Multimodal imaging for quantitative, longitudinal cell tracking in the clinic
Innovation
Mangala Srinivas, CSO, Cenya Imaging; Chair Group Leader,, Wageningen University and Research Centre
May 1914:30
Conference pass
Roundtable: neurological & ophthalmic applications for ATMPs
Cell Therapy
Hardy Tadahisa S Kagimoto, President And Chief Executive Officer, Healios K. K.
May 1914:30
Conference pass
New real-world data: better expansion, PERSISTANCE and disease control of CAR-T
Gene Modified Cell Therapy
May 1914:30
Conference pass
When Rapid Results Matter: The value of QC testing in ATMP
Manufacturing
·Improving the time to result of QC testing with rapid and automated solutions to reduce patient to patient time·Advance safety testing of ATMP from raw materials to product release·Bringing flow cytometry analysis to point-of-need
May 1914:30
Conference pass
miCAR: A novel approach to creating allogeneic CAR T-cell therapies
Innovation
May 1915:00
Conference pass
Caladrius Biosciences; Progress, challenges and learnings during the COVID-19 pandemic
Cell Therapy
- CD34+ cell therapy platform yielding a multi-product development pipeline with 2 clinical programs having regenerative medicine “breakthrough” designation
- Multiple potential value creating events in the next 12-24 months based on milestones across the pipeline
- Strong balance sheet; ~$116 million in cash & investments (2/25/2021) with no debt and cash runway projected to fund operations for several years
May 1915:00
Conference pass
CAR-Macrophages - a novel approach to treating solid tumors
Gene Modified Cell Therapy
Michael Klichinsky, Co-Founder, Vice President Of Discovery And Research, Carisma Therapeutics
May 1915:00
Conference pass
Establishing a process intensification and adaptive manufacturing strategy for CAR-T production
Manufacturing
·Establishing a process control strategy facilitates process intensification, increasing yield and efficiency·Automated strategies for process and product development enable increased consistency·Improved control allows for the potential of patient-specific adaptive manufacturing
May 1915:00
Conference pass
Streamlining digital transformation and reducing data and process silos in advanced therapeutics
Innovation
·Reducing time to market·Reducing the cost of developing·Ease of scaling and distribution post-FDA approval
Vasu Rangadass, President CEO, L7 Informatics
May 1915:30
Conference pass
Panel discussion: MSCs vs iPSC cells
Cell Therapy
Frank Barry, Scientific Director, Regenerative Medicine Institute
May 1915:30
Conference pass
Panel: Tackling solid tumours
Gene Modified Cell Therapy
·Hurdles to solid tumour cell therapy and novel strategies to overcome·Autologous and allogeneic cell therapy for solid tumours·Potential role for combination cellular therapies
Michael Klichinsky, Co-Founder, Vice President Of Discovery And Research, Carisma Therapeutics
May 1915:30
Conference pass
Journey to the Center of the Cell Therapy – Manufacturing and Analytics
Manufacturing
- Manufacturability and sustainability
- Beyond Development: today and tomorrow trends
- Real live case studies
Stefano Baila, director of operations, Anemocyte
Fabio Fachin, Head Of Cell Therapy Engineering And Automation, Takeda
Francesco Cicirello, Site Quality Head, Adaptimmune
May 1915:30
Conference pass
CAR-T model for gamma-delta T cell therapy for GBM
Innovation
Lei Ding, Lead Scientist, in8bio
May 1916:00
Conference pass
Healios's Hybrid business strategy
Cell Therapy
Hardy Tadahisa S Kagimoto, President And Chief Executive Officer, Healios K. K.
May 1916:00
Conference pass
Unique challenges of delivering complex cell therapies
Manufacturing
- Mastering a Complex Supply Chain
- Overcoming Unique Logistical Challenges
- COVID-19 – Delivering in a Global Pandemic
Maria Cho, VP, Business Development, Dendreon Pharmaceuticals LLC
May 1916:00
Conference pass
The latest advances on a monitoring system integrated bioreactor for 3D cell culture
Innovation
May 1916:30
Conference pass
Cord blood and cord tissue derived cellular therapies for pediatric brain diseases
Cord Blood
- Discuss differences between cord blood and cord tissue cells and their roles in potential treatment of pediatric brain injuries.
- Update results of ongoing studies of cord blood therapies in children with cerebral palsy and autism
- Update results of ongoing studies with cord tissue MSCs in children with autism, babies with HIE
Joanne Kurtzberg, Professor Of Pediatrics And Pathology; Director, Marcus Center For Cellular Cures,, Duke University Medical Center
May 1916:30
Conference pass
Workshop/panel: Stratification of patients for immunotherapy and CAR-T
Gene Modified Cell Therapy
·Developing harmonised immune platforms
May 1916:30
Conference pass
Workshop: product and process characterization and validation
Manufacturing
·Choosing a relevant assay for a certain product, discussing what surrogate markers to go for, pros and cons with those, measurability of output data and sensitivity of the assay·How to handle a change of production system, what does it take from a regulatory point of view to justify that it is still the same product?·Set up of stability studies and stress tests of drug product
May 1916:30
Conference pass
Cell therapy in children’s renal disease
Innovation
May 1916:45
Conference pass
Cord Blood Derived Immune Effector Cells
Cord Blood
John Wagner, Executive Medical Director Of B.M.T. Program, University of Minnesota
May 1917:00
Conference pass
Roundtable: The future of cord blood use. Business models, new uses for CB, ethics of pioneering new trials, updating the delivery room
Cord Blood
·A poll will be taken to learn more about the people who are interested in CB, to learn about their activities in the CB field, and we will show the statistical results in the event and even discuss them
Marcie Finney, Associate Director, Cleveland Cord Blood Center
Charis Ober, Founder And Executive Director, Save the Cord Foundation
John Wagner, Executive Medical Director Of B.M.T. Program, University of Minnesota
Joanne Kurtzberg, Professor Of Pediatrics And Pathology; Director, Marcus Center For Cellular Cures,, Duke University Medical Center
May 1917:00
Conference pass
Development of SARS-CoV-2-Specific T cells for the treatment and prevention of infection in immune compromised patients
Gene Modified Cell Therapy
Susan Conway, Critical Care Specialist, Children's National Medical Center
May 1917:00
Conference pass
Roundtable: Suspension, perfusion and continuous processing
Manufacturing
May 1917:00
Conference pass
Generating a patient specific thymus
Innovation
·Developing a thymus ex vivo for transplant
May 1917:30
Conference pass
Immunotherapy keynote: Precision medicine tools have played a role in establishing PD-1 antibodies as foundational monotherapy for- and have informed combination therapies for cancer
Keynotes
- PD-1 Antibodies have become foundational as monotherapy in a number of cancers and new data continue to accumulate
- Precision Medicine Tools enable patient selection and provide information regarding resistance biology
- This information informs on combination therapy selections and an expanding number of these are further transforming cancer treatment
Create your personal agenda –check the favourite icon
May 2012:00
Conference pass
Keynote panel discussion: Where are we with COVID now?
Keynotes
·There are 70+ CT clinical trials registered for COVID and ARDS related to COVID·Round up of COVID & ARDs related CT clinical trials·What are the short term and long-term effects of COVID on the industry going forward?·Head to head comparison of data from key players·Regulatory standpoint on cell therapies for COVID ARDs
Hardy Tadahisa S Kagimoto, President And Chief Executive Officer, Healios K. K.
Susan Conway, Critical Care Specialist, Children's National Medical Center
May 2012:30
Conference pass
Advanced Therapies: development and regulation, from an EU point of view
Keynotes
Live presentation and audience Q&A
Klaus Cichutek, President, Paul Ehrlich Institute
May 2013:00
Conference pass
Keynote panel discussion: The next generation of gene therapy
Keynotes
·Latest technology updates·Scientific nuances, new indications + clinical design
Birgitte Volck, Non Executive Director, Soleno Therapeutics
May 2014:00
Conference pass
Panel discussion: Immunogenicity for gene therapy
Gene Therapy
Key unresolved clinical issues in gene therapy: immunosuppression, re-dosing, and in-utero dosing
Joery De Kock, Professor, Vrije Universiteit Brussel
May 2014:00
Conference pass
Beyond “one disease at a time” : Increasing efficiency in rare genetic disease therapeutics development
Rare disease
May 2014:00
Conference pass
Episomal gene transfer for gene therapy
Innovation
·The Mitotic Stabilityof the episomes within the host cell·The Deliveryissue of non-viral episomes into cells
Aristides D Tagalakis, Senior Lecturer, Edge Hill University
May 2014:30
Conference pass
Gene therapy strategies for rare diseases
Rare disease
Graciana Diez-Roux, Chief Scientific Officer, Telethon Institute of Genetics and Medicine
May 2014:30
Conference pass
Cell & gene therapy manufacturing from concept to patient
Manufacturing
·Capsids: full vs empty vs partially filled
Hartmut Tintrup, Global Head of Business Development, Lonza
May 2014:30
Conference pass
Update on Phase 1 study of AGT103-T: Cell and gene therapy for HIV disease
Innovation
·Implementing a GMP manufacturing process·Product characteristics including new product identity profiles·Real world results on cell yields and potency
May 2015:00
Conference pass
Workshop: Novel gene delivery systems: what’s available? Exosomes, transposons etc. considerations, challenges
Gene Therapy
Phillip Tai, Assistant Professor, University of Massachusetts Medical School
May 2015:00
Conference pass
Roundtable: Translating the technique of gene editing into new treatments
Rare disease
Graciana Diez-Roux, Chief Scientific Officer, Telethon Institute of Genetics and Medicine
May 2015:00
Conference pass
Advancing technologies to better enable Cell & Gene therapies
Manufacturing
The development of advanced therapies is supported by new and evolving technologies. From discovery to manufacture, therapeutics developers and technology providers must work closely together to establish the next generation of tools to address current and future requirements. In this presentation, we discuss how cell and gene therapy reagents and instrumentation are developed and optimized to address the specific needs of therapeutic developers.
Nathan Allen, Director, Product Management, Bio-Techne
May 2015:00
Conference pass
Using Plasticell combinatorial screening technology for optimisation of gene therapy for rare diseases
Innovation
May 2015:30
Conference pass
Roundtable: Moving from ultra-orphan to more common diseases
Gene Therapy
Birgitte Volck, Non Executive Director, Soleno Therapeutics
May 2015:30
Conference pass
Development of a Manufacturing Platform Process for Multiple AAV Gene Therapy Vectors
Manufacturing
- Leveraging platform based approaches to accelerate the development of cGMP compliant processes for manufacturing viral gene therapy products from pre-clinical stages to the clinic
- Establishment of a comprehensive, end-to-end service offering, including HEK293 suspension master cell bank, cGMP plasmid process development and manufacturing capabilities, and drug substance / drug product manufacture
- Flexible approaches to producing other viral vectors to support cell & gene therapy and vaccine products
May 2015:30
Conference pass
Avoiding the endosomal trap through membrane fusion: Efficient delivery of CRISPR protein systems in vitro and in vivo
Innovation
May 2016:00
Conference pass
CRISPR’s Progress for Patients: Clinical Development of Therapies
Gene Editing
May 2016:00
Conference pass
New technologies related to engineering AAV production systems and engineering enhanced promoters for transgene expression
Manufacturing
May 2016:00
Conference pass
Discovery of therapies for infections due to drug resistant bacteria
Innovation
Masahide Yano, Director/Principal Investigator, Hsiri Therapeutics
May 2016:15
Conference pass
Development of ARCUS-based Allogeneic CAR-T Cell Therapies
Gene Editing
·Discussing patient conditioning without biologic immunodepletion·Outlining dosing considerations·Evaluating cell expansion, persistence, and durability of response
Mark Johnson, Clinical Translational Scientist, Precision BioSciences
May 2016:30
Conference pass
Q&A panel: what’s next in ex-vivo gene therapy and gene editing?
Gene Editing
Sven Kili, CEO, Antion Biosciences, Principal, Sven Kili Consulting
Mark Johnson, Clinical Translational Scientist, Precision BioSciences
Pascal Touchon, President, Chief Executive Officer And Board Member, Atara Biotherapeutics
May 2016:30
Conference pass
Economics of viral vector manufacture for cell and gene therapy commercialisation
Manufacturing
May 2016:30
Conference pass
Innovations in immune monitoring technologies to monitor the immune system for next generation ATMPs
Innovation
May 2017:00
Conference pass
Bioethics discussion: Silencing the extra chromosome in trisomy 21: Bioethics of eliminating Down’s syndrome at a cellular level
Gene Editing
·Current state of experimental procedures·Potential Impacts on affected individuals, family and society·Ethical frameworks to consider
May 2017:00
Conference pass
Technologizing ATMP Processes – Efficient methods to enhance NK functionality
Manufacturing
·Are NK-Cells really so shear sensitive, that they can survive stirred/shaked conditions?·Can we treat NK to adapt to defined media to cut the dependency to the supply chain and to reduce costs?·Is a change in metabolism due to different growth conditions also effecting functionality?
Create your personal agenda –check the favourite icon
May 2111:30
Conference pass
Keynote panel discussion: Tackling large-scale, commercial regulatory
Keynotes
·Regulatory harmonisation issues·Covering multiple regions·Aligning regulatory approvals·State of affairs: a lot of modernisation
Janet Glassford, Senior Quality Assessor, Medicines & Healthcare Products Regulatory Agency
May 2112:30
Conference pass
Strengthening the chain of custody data stream in the cell and gene therapy supply chain
Keynotes
·Services and systems integration through consolidation and strategic partnership·Implementation of process and data integration·Optimization of supply chain workflow
May 2113:00
Conference pass
Keynote panel discussion: Finding the right framework for reimbursement and market access for cell and gene therapies
Keynotes
·Europe vs USA vs ROW?·Reimbursement strategies·What’s driving the decision makers at country and national level?
Jie Zhang, Head of Global Value and Access, Cell & Gene, Oncology, Novartis
Luc Boileau, Chairman And Chief Executive Officer, INESSS
May 2113:30
Conference pass
Panel: Cross-border healthcare in Europe
Pricing & Market Access
May 2113:30
Conference pass
Overcoming pain points in the CGT value chain by creating a scalable and collaborative ecosystem
Commercialisation
·This session will feature interviews with leaders in Biopharma and logistics as they discuss their pain points as they move cell and gene therapies into commercialization.
Mark Chalmers, Partner, Life Sciences Commercial Access, EY
Marika Russo, Market Access Director, Novartis Gene Therapies
Jie Zhang, Head of Global Value and Access, Cell & Gene, Oncology, Novartis
Orlando Serani, Program Architect CAR-T, Advanced Cellular Therapies Supply Chain, Johnson & Johnson
Lung-I Cheng, Head of Global Value & Access, Cell Therapies, Takeda Pharmaceutical Company Ltd.
Ariette Van Strien, President, Marken
Adlai Goldberg, Social and Commercial Innovation Leader, EY
May 2113:30
Conference pass
Panel: Patient Delivery in the COVID environment
Patient delivery including logistics, transportation & distribution
Kris Elverum, Senior Vice President Of Business Development And Strategy, Rubius Therapeutics
Jim Kovach, Director, Innovation
May 2113:30
Conference pass
Regulatory session for academic and early-stage companies: Regulatory submissions: gathering the evidence
Innovation
Margareth Jorvid, Head of Regulatory Affairs, Ilya Pharma
Nneka Onwudiwe, Founder And Chief Executive Officer, Pharmaceutical Economics Consultants of America (PECA) LLC
May 2114:00
Conference pass
Roundtable: How and when you should talk to the regulators
Innovation
·Rules vs expectations·Examples·‘Interact scheme’ FDA – est. 2018
Margareth Jorvid, Head of Regulatory Affairs, Ilya Pharma
May 2114:10
Conference pass
What’s worked well in patient delivery?
Patient delivery including logistics, transportation & distribution
May 2114:30
Conference pass
Roundtable: Business development strategies
Commercialisation
Kris Elverum, Senior Vice President Of Business Development And Strategy, Rubius Therapeutics
May 2114:30
Conference pass
Strategies, tech transfer & supply chain: challenges and scale up of product for patient delivery at cryogenic temperatures
Patient delivery including logistics, transportation & distribution
Moderator: David Lewandowski, Director, Business Development, Cell and Gene Therapy, Brooks Life Sciences
Emily Hopewell, Director of Cell and Gene Therapy Manufacturing, Indiana University School of Medicine
Lizette Caballero, Regional CAR-T Site Liaison, Janssen
May 2114:30
Conference pass
Advancing better, safer technologies for preserving future medicines
Innovation
Gary Walsh, Sales Director, Europe, Stirling Ultracold
May 2115:00
Conference pass
Panel: Outcome based agreements
Pricing & Market Access
May 2115:00
Conference pass
Developing an Ideal CAR-T Patient Experience
Patient delivery including logistics, transportation & distribution
- Significant opportunities exist to improve the patient experience centered around patient information sharing
- Leveraging Human Centered Design can dramatically and positively impact the patient experience
- Through this process not only was the patient experience improved, but staff experience was also improved as was efficiency and teamwork
Allison Matthews, Service Designer, Mayo Clinic Center for Innovation
May 2115:00
Conference pass
Cell and Gene therapy standardisation
Innovation
May 2115:30
Conference pass
Roundtable: All the things you were too afraid to ask about funding a new technology or financing a new company
Investment
Moderator: Sven Kili, CEO, Antion Biosciences, Principal, Sven Kili Consulting
Owen Smith, Investment Director, 4BIO Capital
May 2115:30
Conference pass
Looking at value for advanced therapies in Quebec
Commercialisation
Luc Boileau, Chairman And Chief Executive Officer, INESSS
May 2115:30
Conference pass
Panel: Technology Evolution and Supply Chain
Patient delivery including logistics, transportation & distribution
Chris McClain, Senior Vice President, Sales and Business Development, Be The Match BioTherapies
Buzz Bies, Sr. Vice President & Chief Commercial Officer, MVE Biological Solutions
Joseph Garrity, Head of Autologous Cell Therapy Associate Director, Commercial Development, Lonza
May 2115:30
Conference pass
The need to Create a collaborative network to provide a framework for hiPSC generation of hiPSC homozygous for frequent HLA haplotypes
Innovation
May 2116:00
Conference pass
Perspectives on the ATMP Regulatory landscape: approaches to harmonisation and identifying early translational issues
Pricing & Market Access
- Introduction to the Accelerating Research & Development for Advanced Therapies (ARDAT) project
- Regulatory issues encountered during early stage ATMP development in small biotechs and SMEs
- Future scope and tools for regulatory harmonisation and improving ATMP development
Christopher Mann, Scientific And Regulatory Affairs Director, Asphalion, S.L.
May 2116:00
Conference pass
Gates Biomanufacturing Facility: The Experience of Building a Multi-product Cell Therapy/Biologics Phase I cGMP Facility
Innovation
Matthew Seefeldt, Executive Director, The Charles Gates Biomanufacturing Facility
May 2116:30
Conference pass
Panel: VC financing during COVID
Investment
·Money is flowing freely·What happens once these funds are paid out?·What drove them to high valuations? (without having met in person, over zoom)
Sven Kili, CEO, Antion Biosciences, Principal, Sven Kili Consulting
May 2116:30
Conference pass
Workshop: Financing, innovation & company creation
Commercialisation
·How to scale up your business to a commercial level
Kris Elverum, Senior Vice President Of Business Development And Strategy, Rubius Therapeutics
Pierre-Albert Colcomb, GENETHON
May 2116:30
Conference pass
Workshop: New commercial products: moving from clinical to commercial
Patient delivery including logistics, transportation & distribution
·Interacting with pharma companies (i.e. how to administer X)·Moving from bags to vialsoPreparing the dose on-site, how to calculate the correct dosage all the way to patient delivery·POC/commercialisation·Moving from proprietary -> streamlining·Allogeneic:oDosage/amountoDispensing as a pharmacyoVerification process
May 2116:30
Conference pass
Attracting, Retaining & Training Talent
Innovation
Where are the skills shortages? What can be done to train the next generation of talent to minimise the shortage of experts in this area and advance the collective area of advanced therapies for patient benefit?
Moderator: Francesca Gliubich, Director, London Advanced Therapies
Penny Morton, Programme Manager, MRC-UKRI
Kate Barlow, Director of Research Platform Transition, King's College London
Yvette Cleland, CEO, CPL Life Sciences
Uta Griesenbach, Professor, Molecular Medicine, National Heart And Lung Institute; President, British Society For Gene And Cell Therapy;, Imperiai College London
Matthew Cob, Clinical Account Manager, Miltenyi Biotec
Francesco Dazzi, Professor Of Regenerative And Hematological Medicine, King's College London
May 2117:00
Conference pass
Quell Therapeutics Case Study - Building and funding the journey to develop an engineered Treg cell therapy platform
Investment
May 2117:00
Conference pass
Tech Transfer - Driving Translation from Academia to Industry
Commercialisation
·The effectiveness of the Gates Grubstake Program to advance regenerative medicine therapies to the clinic & industry
May 2117:00
Conference pass
Workshop: Bedside delivery of cell therapy nursing perspective
Patient delivery including logistics, transportation & distribution
·Screening patients·Infusion related issues and how to avoid them·Avoiding neurotoxicity·Monitoring after cell infusion·How to spot signs of complications·Finding the right medication·Working with other departments
Matthew J Frigault, Clinical Director, Cellular Immunotherapy Program, Massachusetts General Hospital
Sara Geary Alexander, Clinical Nurse Specialist, Massachusetts General Hospital
Claudia Diamonte, Clinical Trials Nurse, Memorial Sloan-Kettering Cancer Center
last published: 10/May/21 08:45 GMT
Organiser
